These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6726301)

  • 1. Illusion and reality: practical pitfalls in interpreting clinical trials.
    Glatstein E; Makuch RW
    J Clin Oncol; 1984 May; 2(5):488-97. PubMed ID: 6726301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [From empiricism to therapeutic trials. Or how statistical methods can contribute to the improvement of therapeutic protocols in cervicofacial oncology].
    Cachin Y; Flamant R; Richard J; Sancho-Garnier H
    Ann Otolaryngol Chir Cervicofac; 1982; 99(1-2):47-52. PubMed ID: 7103330
    [No Abstract]   [Full Text] [Related]  

  • 3. Proceedings of the Symposium on Designs for Clinical Cancer Reseach. Discussion I: Basic design considerations.
    Cancer Treat Rep; 1980; 64(2-3):411-7. PubMed ID: 7407778
    [No Abstract]   [Full Text] [Related]  

  • 4. Scientific rigour in psycho-oncology trials: why and how to avoid common statistical errors.
    Bell ML; Olivier J; King MT
    Psychooncology; 2013 Mar; 22(3):499-505. PubMed ID: 22315186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential clinical trials in cancer research.
    George SL
    Cancer Treat Rep; 1980; 64(2-3):393-7. PubMed ID: 7407775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers to clinical trial recruitment in head and neck cancer.
    Haddad RI; Chan AT; Vermorken JB
    Oral Oncol; 2015 Mar; 51(3):203-11. PubMed ID: 25593017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing for cancer clinical trials: selection of prognostic factors.
    Brown BW
    Cancer Treat Rep; 1980; 64(2-3):499-502. PubMed ID: 7407790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
    Bellera CA; Pulido M; Gourgou S; Collette L; Doussau A; Kramar A; Dabakuyo TS; Ouali M; Auperin A; Filleron T; Fortpied C; Le Tourneau C; Paoletti X; Mauer M; Mathoulin-Pélissier S; Bonnetain F
    Eur J Cancer; 2013 Mar; 49(4):769-81. PubMed ID: 23122780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial design in head and neck cancer: what has the oncologist learned?
    Adelstein DJ
    Lancet Oncol; 2012 Jul; 13(7):e318-23. PubMed ID: 22748271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perils of the Pathologic Complete Response.
    Rose BS; Winer EP; Mamon HJ
    J Clin Oncol; 2016 Nov; 34(33):3959-3962. PubMed ID: 27551115
    [No Abstract]   [Full Text] [Related]  

  • 11. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Core symptom measures in cancer clinical trials.
    Gotay C
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 25006193
    [No Abstract]   [Full Text] [Related]  

  • 13. Proceedings of the Symposium on Designs for Clinical Cancer Research. Perspective of the clinician.
    Hoogstraten B
    Cancer Treat Rep; 1980; 64(2-3):537-8. PubMed ID: 7407796
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical trials and survival curves: the shape of things to come.
    Elfenbein GJ
    Acta Haematol; 2001; 105(3):188-94. PubMed ID: 11463994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of survival in cancer clinical trials.
    Shimm D; Logue G
    Ann Intern Med; 1983 May; 98(5 Pt 1):665-6. PubMed ID: 6846980
    [No Abstract]   [Full Text] [Related]  

  • 16. Design and performance of clinical trials in head and neck cancer.
    Awada A; Lacombe D; Liberatoscioli C
    Curr Opin Oncol; 2010 May; 22(3):184-5. PubMed ID: 20150810
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
    Herbst RS; Bajorin DF; Bleiberg H; Blum D; Hao D; Johnson BE; Ozols RF; Demetri GD; Ganz PA; Kris MG; Levin B; Markman M; Raghavan D; Reaman GH; Sawaya R; Schuchter LM; Sweetenham JW; Vahdat LT; Vokes EE; Winn RJ; Mayer RJ;
    J Clin Oncol; 2006 Jan; 24(1):190-205. PubMed ID: 16326753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Haddad et al. Barriers to clinical trial recruitment in head and neck cancer.
    Main BG
    Oral Oncol; 2015 May; 51(5):e22. PubMed ID: 25795374
    [No Abstract]   [Full Text] [Related]  

  • 19. Performing serial testing of treatment effects.
    Fleming TR; Green SJ; Harrington DP
    Experientia Suppl; 1982; 41():469-84. PubMed ID: 6958531
    [No Abstract]   [Full Text] [Related]  

  • 20. Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator's primer.
    Simes RJ; Zelen M
    J Clin Oncol; 1985 Oct; 3(10):1418-31. PubMed ID: 4045529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.